Upcoming webinar explores how health systems can prepare for infant RSV immunisation programmes
25 September 2024
On 21 October at 14:00 CET, The Health Policy Partnership (HPP) will host a free webinar to launch the report Protecting infants from RSV through effective immunisation strategies.
HPP Director of Research Jody Tate will be joined by members of the report’s expert Steering Committee to discuss their experiences of implementing immunisation programmes for respiratory syncytial virus (RSV) in France, Spain and the US. The webinar will be an opportunity to hear directly from the panel as they talk about key success factors and how they addressed any challenges that arose.
RSV is a common virus that infects most children by the time they are two years old. Although RSV usually causes mild cold- or flu-like symptoms, in some cases, it can lead to serious respiratory infection. RSV is the leading cause of bronchiolitis and pneumonia in infants and the leading cause of hospitalisation for children in their first year of life.
These hospitalisations place significant pressure on families and health systems. No targeted treatment for RSV is currently available, meaning prevention is key to protecting infants from hospitalisation. Significant advances in recent years have seen several immunisation strategies become available, including a vaccine administered during pregnancy and a long-acting monoclonal antibody (mAb), which provide protection for infants.
As an increasing number of countries are beginning to implement RSV immunisation programmes using these new and emerging strategies, the webinar aims to share the lessons taken from existing programmes to help policymakers and health system planners prepare to implement their own.
During the webinar, we will also be launching a new report which further examines the considerations policy- and decision-makers should be aware of. The report builds on the implementation framework released earlier this year to support designing and delivering immunisation programmes using the long-acting mAb for RSV.
The webinar and report were developed as part of a non-promotional research project funded by Sanofi and AstraZeneca and led by HPP. All outputs are non-promotional and evidence based. Editorial control for the project is held by the project Steering Committee, who were not paid for their time in relation to the research project. No speakers involved in this webinar were paid for their time other than those who are employees of HPP. For more information, please visit the project page.
We hope you can join us at this event.
